Company intelligence / Profile preview

Opexa Therapeutics

The Woodlands, Texas, United Statesopexatherapeutics.com ↗

Ownership: Private
Development stage: Other

Overview

Opexa’s lead program, Tcelna®—a personalized autologous T-cell immunotherapy—completed a Phase IIb trial (“Abili-T”) in Secondary Progressive Multiple Sclerosis but failed to meet its primary or secondary endpoints. The company underwent significant restructuring after the negative results and ceased active operations by 2017[3]. No products have reached commercialization.

Therapeutic areas: Neurology
Modalities: Autologous cell therapyPersonalized immunotherapyT-cell therapyAdult stem cell therapy (investigational)
Industry: Biotech

Partnerships

No major pharmaceutical partnerships reported. Early technology licensed from Baylor College of Medicine and University of Chicago.[7]

Beyond the preview

Go deeper on Opexa Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Opexa Therapeutics.

Explore the full profile